Loading
DAN-222 is an experimental high-capacity drug conjugate from Dantari, in phase 2 trials for HER2-negative metastatic breast cancer; its current status is not stated.
DAN-222 is a high-capacity drug conjugate (polymer-based) from Dantari. A high-capacity drug conjugate carrying a topoisomerase 1 inhibitor payload. Its furthest stage is phase 2, for HER2-negative metastatic breast cancer. ClinicalTrials.gov registers it in 2 studies linked below. Own phase 1 NCT05261269 completed; the I-SPY phase 2 platform arm 'Dan222 + Niraparib' is closed. Company status not verified (domain parked). Whether it works in people has not been established unless a trial below reports it.
A high-capacity drug conjugate carrying a topoisomerase 1 inhibitor payload.
1.DAN-222's antibody arm binds its target on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"DAN-222" OR ABSTRACT:"DAN-222") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about DAN-222, not a curated reading list.
Shares Dantari and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/